Alembic Pharmaceuticals Receives USFDA Tentative Approval for Larotrectinib Capsules
Alembic Pharmaceuticals has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. This drug is therapeutically equivalent to Bayer's Vitrakvi Capsules and is used to treat adult and pediatric patients with solid tumors harboring NTRK gene fusion, particularly in metastatic cases or when surgery poses severe risks. The Larotrectinib market is estimated at US$91 million for the year ending March 2026. Alembic's Q4 FY26 net profit rose 29.19% to Rs 202.70 crore, with revenue increasing 4.41% year-on-year.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is positive (72/100). Lens Score 34/100 — low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- businessstandard— balanced framing, positive sentiment
- businessstandard— balanced framing, positive sentiment
AI Analysis
The articles focus on corporate and regulatory developments without political framing. Coverage centers on Alembic Pharmaceuticals' regulatory approval and financial performance, reflecting business and healthcare industry perspectives. There is no evident political viewpoint or partisan framing, as the content is primarily factual and industry-specific.
The overall tone is positive, highlighting Alembic Pharmaceuticals' regulatory milestone and financial growth. The language is neutral and factual, emphasizing achievements without exaggeration. The sentiment reflects optimism about the company's product approval and market potential, balanced with straightforward reporting of financial results.
How 2 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.